Introduction
Magnaporthe oryzae (Hebert) ME Barr, an
ascomycete fungus, causes blast disease in rice (Yang et al. 2009; Yan
et al. 2013). Every year,
this disease wreaked havoc incurring millions of
dollars’ economic losses (Chen et al.
2019). The continuous decrease in
cultivable land and limited water resource further aggravate the problem (Talbot
2003). Until now, the fungal pathogen
was controlled by using fungicides (Liu et al. 2012; Lopez and
Cumagun 2019; Jeon et al. 2020).
Since 1970s, various azole fungicides like propiconazole, diniconazole,
triadimefon, triadimenol and tebuconazole have been widely used to prevent the
attack of fungal pathogens. Since most of these modern fungicides exhibit a
similar mode of action, resistant strains have re-surfaced, resulting in
infected crops and the situation were exacerbated (Parker et
al. 2011; Chowdhary et al. 2012; Price et al. 2015).
Most of the azole fungicides are the inhibitors
of the biosynthesis of ergosterol, the predominant sterol component of the
fungal cell membrane (Yang et al. 2009). The process is initiated by the binding of azoles with the CYP51
protein (Parker et al. 2011). Conserved residues of CYP51s are mostly clustered into 6 substrate
recognition sites (SRSs) and the heme binding region (Lepesheva
and Waterman 2007). Based on the
crystal structure of CYP51 from Aspergillus
fumigatus, SRS1 (helix B’’ and B’C loop), SRS2 (helix F’’), helix C, SRS4
(the N-terminal portion of helix I), SRS5 (K helix-β1–4 loop) and SRS6
(β4 hairpin) form the active cavity related to substrate recognition and
interaction (Hargrove et al. 2015). Some relationships of structure and function have been thoroughly
studied on SRS regions, elucidated the importance of specific residues (Lamb
et al. 1998; Hargrove et al. 2011). Mutation of these specific residues lowered the binding affinity of
azoles without affecting expression of the protein. Unlike many other classes
of fungicide where a single amino acid substitution in the target protein would
lead to drug resistance, a combination of alterations in the CYP51 was required
for effective azole resistance.
Several
paralogs of the CYP51 were usually found in various fungal genomes
named as CYP51A, B and C, with CYP51C being reported exclusively from Fusarium (Fan et
al. 2013).
Fungi with multiple CYP51s have inherent resistance to azoles, although some
azole fungicides still effective against almost all pathogenic
fungus. For instance, although fluconazole is ineffective, voriconazole and itraconazole control A. fumigatus very well.
Resistance to azole drugs in fungi with multiple CYP51s is mainly
mediated by the change of CYP51B (Gao et al. 2018). Thus, CYP51B
could be stated as an important target region in M. oryzae for antifungal drug development.
In this
study, we investigated the roles of several key conserved residues of SRS5 and
SRS6 domains of the of CYP51 protein from M. oryzae (MoCYP51B)
in
binding to diniconazole. Through site directed mutagenesis and binding spectra
analysis, we revealed the important roles of I367 and V374 in azole
sensitivity. Both the residues conserved amino
acids in the SRS5 region of MoCYP51B. This study provides additional evidence in support of the role of SRS5
region of CYP51B protein in azole binding in addition to
broadening our knowledge about the various amino acid residues contributing to
this interaction. This information will probably take us a step further in
designing effective and specific inhibitors against pathogenic attack.
Materials
and Methods
Strains
Wild-type M. oryzae was obtained
from the Agricultural Culture Collection of China (ACCC
preservation number 30320), Beijing, China. Fungal spores were preserved in
sterile water storage at room temperature. Escherichia coli BL21
(DE3) were purchased from Novagen (Germany). Bacterial cultures were
maintained in glycerol stocks at -80℃. Working stocks were maintained as
liquid cultures at 4℃.
Cloning of
the MoCYP51B gene and construction of
expression vector
Genomic DNA was extracted using the E.Z.N.A. DNA kit (Omega, USA), and
the DNA concentration was measured at OD260 by NanoDrop™
2000 spectrophotometer (Thermo Fisher Scientific, U.S.A.).
The truncate MoCYP51B was amplified
using primers F (5’-GATATCCGTCCCAAATCGGAACCA-3’) and R (5’-CCGCTCGAGTTGTCATTCTACGCAGTCTTCG-3’),
with inserted
EcoRV and XhoI restriction
sites, respectively. The DNA fragment ligated to pET30a (+) vector (Novagen, Germany).
The success of the cloning was cross-checked
with enzyme digestion of the plasmid followed by sequencing.
Sequence
alignment and analysis of CYP51s
The nucleotide and amino acid sequences were obtained from the cytochrome
P450 homepage and NCBI Data Bank. In order to compare the inter specific amino
acid sequences of CYP51s, the nucleotide sequences of cyp51 exons across species were
translated into their corresponding amino acids using the software EMBOSS:
transeq (http://www.ebi.ac.uk/emboss/transeq/). The sequences were aligned,
using the clustalW 1.82 program (http://www.ebi.ac.uk/clustalw/).
Site-directed
mutagenesis
Several key conserved amino acids in
SRS5 and SRS6 domains of CYP51 family were selected for site-directed
mutagenesis. Desired mutations were introduced into pET30a (+)-MoCYP51B using a site-directed
mutagenesis kit (SBS Genetech Co., Ltd., China), using
200 ng of (pET30a(+)-MoCYP51B)
plasmid and 10 μM
of each primer (Table 1).
Expression
and extraction of recombinant proteins
The constructed plasmid pET30a (+)-MoCYP51B
was transformed into E. coli BL21(DE3). The cells were cultivated at 37℃
and 210 rpm in LB medium and
OD600
was checked to determine the growth phase of the culture every 2 h. After the cultures reached the desired OD600 of 0.5–0.6, 0.5 mM IPTG was
added. Cells were harvested after
2 h, and the bacterial pellet
obtained from 1 L of initial culture was suspended in 50 mL 25 mM Tris-HCl (pH 7.5) and kept at -70℃. Frozen cells were sonicated in
Tris-HCl containing 2 mM DTT using an Ultrasonic
Probe 2000 Sonicator (Trading, China) at 30% power for 10
min (10 s sonication, 10 s rest), and centrifuged at 4℃ to remove cell debris. The membrane fractions
were suspended in 100 mM potassium phosphate (pH 7.5) buffer containing
20% glycerol, 1 mM reduced glutathione, and 0.1 mM
EDTA. The
protein content was measured using a bicinchoninic acid protein
assay kit (Sigma-Aldrich, USA) with BSA as a standard.
Western
blot analysis
To detect the wild-type and mutant MoCYP51 proteins, the cell extracts
were fractionated
by SDS-PAGE using 12% gels and transferred to a nitrocellulose membrane
electrophoretically (Novagen,
USA). The
membrane was then probed with mouse anti-His CYP51 IgG, conjugated with anti-mouse IgG (H + L) (Pierce, USA).
Reduced
CO-difference spectrum
The CYP450 protein content and activity were tested as reported
previously (Omura and Sato 1964). In order to record the baseline, microsomal suspensions were reduced with by using a few milligrams of solid sodium dithionite and transferred to quartz cuvettes. A S3100 UV-visible
spectrophotometer (Twin Lakers, USA) was used for all
recording. The contents of the sample cuvettes were subsequently bubbled with
CO for a pulse of 50 s (1 bubble s-1) with simultaneous recording of
the spectral differences. Microsomal P450 (250 pmol) with 5 mM azole fungicide (0.9% DMSO
used as control) was kept on ice briefly (3–5 min). The CO difference spectrum
(reduced) was recorded at a stretch of 50 min with 10 min intervals at the onset
of CO treatment.
Diniconazole
binding spectra
Diniconazole
was purchased from the Factory of Limin (Yancheng, China). Diniconazole binding
spectra were detected by using S3100 UV-visible scanning
spectrophotometer (Sinco, Korea). The baseline was recorded for 250 pmol
microsomal suspensions. Differences in spectra were noted by addition of
increasing concentration of diniconazole (dissolved in DMSO). The data points are fitted to a rectangular hyperbola, and the Kd
value was generated by the equation ∆A = ∆Amax [I]/(Kd + [I]). The binding
experiments were repeated three times and the results were interpreted based on triplicate
observations.
Results
Multiple sequence alignment of CYP51 proteins in fungi
To identify the essential residues for maintaining protein structure and
function, members of CYP51 family from various fungal species were aligned
(Fig. 1). In the SRS5 region, the residues I367, R372 and V374 showed an absolute
conservation nearly in all the species. In the SRS6 region, complete conservation
is observed for S494 and P499. All these residues are marked with the triangle
symbol (Fig. 1). In order to assess the function of conserved amino acids
in MoCYP51B active cavity, amino acid subsets I367, R372, V374 in the SRS5 and S494, P499 in the SRS6 were selected for
site-directed mutagenesis.
Table 1: Primers
used for site-directed mutagenesis
Primer
|
Sequence (5′-3′)
|
Introduced CYP51 mutant
|
Mo-I367Lmut
|
CGGGTGCACTCGTCCCTCCACTCCATCATGC
|
I367L
|
Mo-I367Wmut
|
GGGTGCACTCGTCCTGGCACTCCATCATGCG
|
I367W
|
Mo-R372Dmut
|
ATCCACTCCATCATGGACAAGGTGAAGCGGCC
|
R372D
|
Mo-V374Amut
|
CCATCATGCGCAAGGCGAAGCGGCCGATGC
|
V374A
|
Mo-V374Ymut
|
CCATCATGCGCAAGTACAAGCGGCCGATGCG
|
V374Y
|
Mo-S494Fmut
|
CCCACTGATTACACTTTTATGTTCTCTCGGCCT
|
S494F
|
Mo-S494Tmut
|
CCCACTGATTACACTACTATGTTCTCTCGGC
|
S494T
|
Mo-P499Emut
|
TCTATGTTCTCTCGGGAGATGCAGCCTGCGACG
|
P499E
|
Mo-P499Qmut
|
TCTATGTTCTCTCGGCAGATGCAGCCTGCGACG
|
P499Q
|
Fig. 1: Multiple alignment of CYP51Bs. The sequences of
DNA and deduced amino acids were aligned using the computer program clustalw 1.82 (http://www.ebi.ac. uk/clustalw/). The conserved residues
in MoCYP51 active cavity for SRS5 and SRS6 are marked with the triangle symbol
Fig. 2: Western
blotting for heterologous expression of recombinant
MoCYP51 proteins. The filter was probed with mouse anti-His CYP51 IgG, conjugated with antimouse IgG (H + L). Untreated: IPTG uninduced
Expression
and detection of wild-type and mutant MoCYP51B proteins
Based on
the results of sequence alignment, the absolute conservation residues were
selected for further analysis. Using site-directed mutagenesis methods, we
mutated I367, R372, V374 and S494, P499 in
the SRS5 and SRS6 regions, respectively, followed by the bacterial expression of protein. The motilities
of the MoCYP51B proteins upon expression were coincident with their theoretical
molecular weights (approximately 51 kD). The detection of the band of the protein of
interest was performed by Western blotting (Fig. 2). All the recombinant
proteins produced a CO reduced difference spectrum with Soret peak around 447
nm. Thus, the results suggested a conservation of the functionalities of the
proteins even after introduction of point mutations.
Diniconazole binding
to mutated MoCYP51B protein
The azole fungicide, diniconazole, forms a
type-II binding spectra upon binding to active cavity of the purified MoCYP51B
protein. A similar spectrum with maximum absorbance at 428 nm
and a minimum
at 395 nm has been observed after diniconazole binding with Penicillium
digitatum CYP51
protein (Zhao et
al. 2007). No alteration in the structure and function of the various mutated
MoCYP51B proteins was observed. All the
wild type and mutated proteins bound to diniconazole formed a type-II
binding spectra with with peak located at 410–415 nm and a trough at 375–380 nm. The mutated MoCYP51B proteins could bind to
diniconazole, although Kd values varied (Fig. 3). Compared to
the wild type protein, the Kd values of the
mutations I367L, R372D, V374A, S494F, S494T, P499E and P499Q upon binding to
diniconazole were essentially unchanged, whereas the Kd value of V374Y and I367W increased
significantly (P < 0.05) (Table 2),
indicating that the binding efficiency of these two mutated proteins
significantly decreased. Based on previous results and current spectral analysis, an interaction between
triazoles and the heme of CYP450 lead to the mode
transition to high-spin state can be suggested. In turn, this would cause the sixth ligand of heme iron to be replaced by the nitrogen atom in the
triazole ring of diniconazole (Buckner et al. 2003).
Discussion
The
increased resistance of fungi to azole antibiotics could be due to excessive
use of azole fungicides. However, the complex mechanism of drug resistance in
fungal is still not very clear (Fan et al. 2013). To date, several amino acid residues associated with fungicide sensitivity
in fungal protein CYP51B have been identified. More than 140 different point
mutations in the Candida albicans
CYP51B have been found to lower the binding affinity of the protein to the
fungicide. Of specific interest is the mutataion S279F/Y that had a 4- to 5-folds lower affinity for
fluconazole and 3.5-fold lower affinity for voriconazole in comparison to the
wild-type protein (Warrilow et al. 2012). Azole binding mechanism
to CYP51 protein has been thoroughly studied in Mycosphaerella graminicola. Cools et
al. (2011) suggested that the
substitution S524T of MgCYP51
variants lead to the decreased efficacy of epoxiconazole and prothioconazole. Our previous research identified the
presence of a hydrophobic site P222 in F helix of MoCYP51, which could play a
very important role in modulating the affinity for azole fungicides (Liao
et al. 2015). In this study,
several important conserved amino acids in these two domains of MoCYP51B were
mutated followed by thorough binding analysis via spectophotometry. The results showed that the conserved
residues I367 and V374 in SRS5
contribute to diniconazole binding and mutations I367W and V374Y significantly reduced the binding affinity.
Table 2: The Kd value of
recombinant protein bound to diniconazole
Recombinant
protein |
Regressive equation |
Kd ±
SD(μM) |
Wild-type |
y = 2.4439x - 0.0493 |
0.017 ± 0.004 |
I367L |
y =
1.0457x + 0.1143 |
0.042 ± 0.007 |
I367W |
y =
1.1572x + 0.0413 |
0.130 ± 0.064 |
R372D |
y =
2.0928x + 0.059 |
0.030 ± 0.002 |
V374A |
y =
0.8165x + 0.0186 |
0.063 ± 0.024 |
V374Y |
y =
0.4748x + 0.0882 |
0.178 ± 0.012 |
S494F |
y =
0.9123x + 0.0822 |
0.056 ± 0.034 |
S494T |
y =
1.0098x + 0.0648 |
0.085 ± 0.030 |
P499E |
y =
1.0981x + 0.0641 |
0.053 ± 0.007 |
P499Q |
y = 1.191x
+ 0.1154 |
0.069 ± 0.040 |
Fig. 3: Binding
spectra in the presence of diniconazole
for the wild type and mutant SRS5 and SRS6 of MoCYP51 (protein content 1
g/L). (a): the wild-type CYP51 protein; (b):
CYP51 with I367L mutation; (c): CYP51 with I367W mutation; (d):
CYP51 with R372D mutation; (e): CYP51 with V374A mutation; (f):
CYP51 with V374Y mutation; (g): CYP51 with S494F mutation; (h):
CYP51 with S494T mutation; (i): CYP51 with P499E mutation; (j):
CYP51 with P499Q mutation. The main section of the figure shows difference
spectra induced by diniconazole binding to wild type
and mutated MoCYP51B proteins. The inset shows the relation between diniconazole concentrations and the magnitude of type-II
difference spectra (A410-415 minus A375-380). The data points are fitted to a
rectangular hyperbola, and the Kd
value was generated by the equation ∆A = ∆Amax [I]/(Kd + [I])
According to the molecular
modeling study of azole agents with C.
albicans CYP51, it was found that residues L376 and S378, either of which
is not conserved in SRS5 of CYP51s family, might play an important role in
binding of the inhibitor or substrate (Chen et al. 2009). It is worth to note that the
substitution of nonpolar hydrophobic residue I367 with the nonpolar aromatic W, concomitantly reduces the binding ability of MoCYP51 to
diniconazole, while a substitution to the nonpolar hydrophobic residue L has no
effect, indicating that the aromatic side chain probably hinders the affinity
towards the azole fungicide. In addition, the
substitution of nonpolar hydrophobic residue V374 by the polar Y reduces the
binding ability of MoCYP51 to diniconazole, whereas the substitution
by nonpolar A had no effect, indicating that the hydrophobicity of this site
may be important for the affinity towards the azole fungicide. According to previous molecular modeling study of azole agents with C. albicans CYP51 (Chen et
al. 2009), it was found that
residues I367 and S378 in the SRS5 region of CYP51 protein played an important
role in inhibitor binding to the substrate.
Strushkevich et al.
(2010) suggested that, in human SRS6 region of CYP51B, the main-chain carbonyl group of M487-corresponding
residue forms a hydrogen bond with the 3β-hydroxy group of substrate
analog aiding substrate recognition. Contrary to these findings, our results
indicate that in M. oryze, conserved
residues of the SRS6 domain of MoCYP51B do not contribute to substrate
sensitivity. Specifically, point mutations resulting in the substitutions
S494T/F and P499E/Q in SRS6 domain of MoCYP51B have no effect on the binding
intensity of the protein to azoles. Recent outbreaks of resistant
strains of MoCYP51 variants have limited the affectivity of the most potent
azole fungicides. Until and unless this evolution of the newer variants is kept
on check, the azole drugs will be of little help in near future. An extensive
genetic analysis needs to be carried out to elucidate the mechanisms of
azole-fungi interactions. As the azole drugs have been in use for a long time,
a potential formulation of azole drug combination can only be suggested as a
remedy to arrest the constantly changing molecular machinery of M. oryzae to combat the fungicides.
More understanding of structure/function relations for
key amino acid residues of CYP51 protein will open an opportunity for design of novel highly effective
fungicides. In this paper, we investigated
the azole binding potency of conserved residues of SRS5 and SRS6 regions in
MoCYP51B protein. The data revealed the residues I367 and V374 in MoCYP51B SRS5 had critical contribution to
azole binding. This information
will help for the development of
novel antifungal agents against M.
oryzae.
Conclusion
The amino acid residues I367 and V374 in the MoCYP51B SRS5 played an
important role in the azole binding. Further studies are needed to the design
of effective and specific DMIs for M. oryzae.
Acknowledgements
This
research was supported by the Hubei
Provincial Natural Science Foundation of China (No. 2019CFB265), and the
Research and Innovation Initiatives of WHPU (No. 2019Y03).
Author Contributions
WFL and JYY conceived and designed the experiments; TTL
and WFL performed the experiments; TTL and WJL analyzed the data; JYY contributed
reagents/materials/ analysis tools and WFL wrote the paper.
References
Buckner
FS, K Yokoyama, JW Lockman, K Aikenhead, J Ohkanda, M Sadilek, MH Gelb (2003). A class of sterol 14-demethylase
inhibitors as anti-Trypanosoma cruzi
agents. Proc Natl Acad Sci USA 100:15149‒15153
Chen
SH, CQ Sheng, XH Xu, YY Jiang, WN Zhang, C He (2009). Expression and detection the enzyme activity of the wild
and mutation type of CYP51 protein of Candida albicans. Microbiol Bull 10:1564‒1570
Chen XL, YL
Jia, BM Wu (2019). Evaluation of rice responses to the blast
fungus Magnaporthe oryzae at different growth stages. Plant
Dis 103:132‒136
Chowdhary
A, S Kathuria, HS Randhawa, SN Gaur, CHW Klaassen, JF Meis (2012). Isolation of multiple-triazole-resistant Aspergillus
fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in
India. J Antimicrob Chemother 67:362‒366
Cools HJ, JGL
Mullins, BA Fraaije, JE Parker, DE Kelly, JA Lucas, SL Kelly (2011). Impact of recently emerged sterol 14 alpha-demethylase (CYP51)
variants of Mycosphaerella graminicola on azole fungicide sensitivity.
Appl Environ Microbiol 77:3830‒3837
Fan J, M
Urban, JE Parker, HC Brewer, SL Kelly, KE Hammondkosack, HJ Cools (2013).
Characterization of the sterol 14 alpha-demethylases of Fusarium graminearum
identifies a novel genus-specific CYP51 function. New Phytol 198:821‒835
Gao P, YL Cui, RL Wu (2018). Molecular
dynamic modeling of CYP51B in complex with azole inhibitors. J Biomol
Struct Dyn 36:1511‒1519
Hargrove TY, Z
Wawrzak, DC Lamb, FP Guengerich, GI Lepesheva (2015). Structure-functional
characterization of cytochrome P450 sterol 14 alpha-demethylase (CYP51B) from Aspergillus
fumigatus and molecular basis for the development of antifungal drugs.
J Biol Chem 290:23916‒23934
Hargrove TY, Z
Wawrzak, J Liu, WD Nes, MR Waterman, GI Lepesheva (2011). Substrate preferences
and catalytic parameters determined by structural characteristics of sterol 14 alpha-demethylase (CYP51) from Leishmania infantum.
J Biol Chem 286:26838‒26848
Jeon JB, G
Lee, K Kim, S Park, S Kim, S Kwon, A Huh, H Chung, D
Lee, CW Kim, Y Lee (2020). Transcriptome profiling of the
rice blast fungus Magnaporthe oryzae and its host Oryza sativa during
infection. Mol Plant Microb Interact 33:141‒144
Lamb
DC, DE Kelly, NJ Manning, DW Hollomon, SL Kelly (1998). Expression, purification, reconstitution and inhibition
of Ustilago maydis sterol 14
alpha-demethylase (CYP51; P450(14DM)). FEMS
Microbiol Lett 169:369‒373
Lepesheva GI,
MR Waterman (2007). Sterol 14 alpha-demethylase cytochrome
P450 (CYP51), a P450 in all biological kingdoms. Biochim Biophys Acta
1770:467‒477
Liao WF, TT
Liu, S Yang, GS Zhang, T Shu, JY Yang (2015). Interaction
between the conserved amino acid in Magnaporthe oryzae CYP51F helix and
Diniconazole. Microbiol Bull 42:2433‒2439
Liu H, WX
Tian, B Li, GX Wu, M Ibrahim, ZY Tao, GL Xie (2012). Antifungal effect and
mechanism of chitosan against the rice sheath blight pathogen, Rhizoctonia
solani. Biotechnol Lett 34:2291‒2298
Lopez AL, CJ
Cumagun (2019). Genetic structure of Magnaporthe oryzae
populations in three island groups in the Philippines. Eur J Plant
Pathol 153:101‒118
Omura T, R Sato (1964). The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239:2370‒2378
Parker JE, AGS
Warrilow, HJ Cools, CM Martel, WD Nes, BA Fraaije, SL Kelly (2011). Mechanism
of binding of prothioconazole to Mycosphaerella graminicola CYP51
differs from that of other azole antifungals. Appl
Environ Microb 77:1460‒1465
Price
CL, AGS Warrilow, JE Parker, JGL Mullins, WD Nes, DE Kelly, SL Kelly (2015). Novel substrate specificity and
temperature-sensitive activity of Mycosphaerella graminicola CYP51
supported by the native NADPH Cytochrome P450 reductase. Appl Environ
Microbiol 81:3379‒3386
Strushkevich
N, SA Usanov, HW Park (2010). Structural basis of human cyp51
inhibition by antifungal azoles. J Mol Biol 397:1067‒1078
Talbot NJ
(2003). On the trail of a cereal killer: Exploring the biology of Magnaporthe grisea.
Annu Rev Microbiol 57:177–202
Warrilow AGS, JGL Mullins, CM Hull, JE Parker, DC Lamb, DE Kelly,
SL Kelly (2012). S279 point mutations in candida albicans Sterol
14-alpha Demethylase (CYP51) reduce in vitro
inhibition by fluconazole. Antimicrob Agents Chemother 56:2099‒2107
Yan L, Q Yang,
Y Zhou, X Duan, Z Ma (2013). A real-time PCR assay for quantification of the
Y136F allele in the CYP51 gene associated with Blumeria graminis f. spp.
tritici resistance to sterol
demethylase inhibitors. Crop Prot 28:376‒380
Yang JY, Q Zhang,
MJ Liao, M Xiao, WJ Xiao, S Yang, J Wan (2009). Expression
and homology modelling of sterol 14 alpha-demethylase of Magnaporthe grisea and
its interaction with azoles. Pest Manage Sci 65:260‒265
Zhao L, D Liu, Q Zhang, S Zhang, J
Wan, W Xiao (2007). Expression and homology modeling of sterol 14 alpha-demethylase
from Penicillium digitatum. FEMS Microb
Lett 277:37‒43